Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Projections for the near future indicate that the glucagon-like peptide GLP-1 agonists weight loss drugs market size will continue to surge, reaching $28.91 billion in 2029 at a CAGR of 16.6%.

Background: The use of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has substantially expended given their remarkable benefits in managing obesity. Yet, their impact on long-term cancer risk ...

Background: Obesity is a major risk factor for cancer development. However, whether glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of diabetes medication which causes weight loss, ...

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% meeting criteria for obesity alone, according to the Centers for Disease ...

The explosive popularity of GLP-1 (Glucagon-Like Peptide-1) drugs for addressing weight loss, diabetes and obesity, such as Ozempic and Munjaro are useful for a limited number of people and will ...

Fridays Health is revolutionizing the weight loss journey by offering a holistic and science-backed approach to achieving lasting results. Their innovative use of GLP-1 (glucagon-like peptide-1 ...

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%.